KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA) for Preventing Recurrent Clostridioides difficile Infection.

Ken F Blount, Romeo Papazyan, Nicky Ferdyan, Karthik Srinivasan, Carlos Gonzalez, William D Shannon, Bryan C Fuchs

J Infect Dis 231(6) e1022-e1033

PMID39172632
PMCIDPMC12247815
DOI10.1093/infdis/jiae418
发表日期2024-08-22
入排依据:未发现恶性肿瘤人群证据。
已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:AI 判定为 other;另有 2 张未列出。
摘要

摘要

BACKGROUND: Microbiota-based treatments are effective in preventing recurrent Clostridioides difficile infection. Fecal microbiota, live-jslm (REBYOTA; RBL, previously RBX2660) was shown to prevent recurrent C difficile infection in a phase 3 clinical trial (PUNCH CD3) based on a randomized, double-blinded, placebo-controlled design. METHODS: Stool samples from participants in PUNCH CD3 who received a single blinded dose of rectally administered RBL or placebo were sequenced to determine microbial community composition and calculate the Microbiome Health Index for postantibiotic dysbiosis. The composition of bile acids (BAs) in the same samples was quantified by liquid chromatography-mass spectrometry. Relationships between BA composition and microbiota community structure and correlations with treatment outcomes were assessed. RESULTS: Before administration, Gammaproteobacteria and Bacilli dominated the microbiota community, and primary BAs were more prevalent than secondary BAs. Clinical success after administration correlated with shifts to predominantly Bacteroidia and Clostridia, a significant increase in Microbiome Health Index for postantibiotic dysbiosis, and a shift from primary to secondary BAs. Several microbiota and BA changes were more extensive in RBL-treated responders as compared with placebo-treated responders, and microbiota changes correlated with BA changes. CONCLUSIONS: Clinical response and RBL administration were associated with significant restoration of microbiota and BA composition. CLINICAL TRIALS REGISTRATION: NCT03244644 (https://clinicaltrials.gov/ct2/show/NCT03244644).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Overall microbiota composition changes in trial participants. Nonmetric multidimensional Bray-Curtis dissimilarity analysis for microbiota compositions of RBL and treatment responders over time: A , RBL responders; B , placebo responders; C , treatment nonresponders. BL, baseline; M, months; RBL, fecal microbiota, live-jslm; W, weeks.
非 KM Figure
Figure 2Figure 2. Effect size (ϕ) of treatment responders' microbiota as compared with RBL composition. BL, baseline; M, months; RBL, fecal microbiota, live-jslm; W, weeks.
非 KM Figure
Figure 3Figure 3. Relative abundance at the taxonomic class level: A , RBL responders; B , placebo responders; C , treatment nonresponders. Sample numbers per group are indicated in Supplementary Table 1. Bars indicate 95% CIs around the mean (π), denoted as a line. Actino, Actinomycetia; Bacter, Bacteroidia; BL, baseline; Clost, Clostridia; Erysi, Erysipelotrichia; Gamma, Gammaproteobacteria; M, months; Negat, Negativicutes; RBL, fecal microbiota, live-jslm; W, weeks.
非 KM Figure
Figure 4Figure 4. Repeated measures analysis of the relative abundance in trial participants: A , Bacteroidia; B , Clostridia; C , Gammaproteobacteria; D , Bacilli. Data are presented as mean and 95% CIs for each indicated time point. BL, baseline; M, months; RBL, fecal microbiota, live-jslm; W, weeks.
非 KM Figure
Figure 5Figure 5. Microbiome Health Index values over time in treatment responders ( A ) and nonresponders ( B ) and alpha diversity over time in treatment responders ( C ) and nonresponders ( D ). Sample numbers per group are indicated in Supplementary Table 1. For Microbiome Health Index values, median values are denoted with a bar. For Shannon index, mean (bar), IQR, and range are shown. BL, baseline; M, months; MHI-A, Microbiome Health Index for postantibiotic dysbiosis; RBL, fecal microbiota, live-jslm; W, weeks.
非 KM Figure
Figure 6Figure 6. Large-scale bile acid changes detected in trial participants. Heat map of bile acid levels (ng/g) in wet fecal samples from treatment responders and nonresponders. Increasing bile acid concentrations (darker colors) are shown, including below the limit of detection (white). Annotations in boxes above the heat map include bile acids as follows: primary (light gray) or secondary (dark gray); conjugated (green) or nonconjugated (white); and 7-hydroxylation (7-OH, blue), 7-oxo (7 = O, red), or 7-dehydroxylated (7-H, taupe). Sample numbers per time point are indicated in Supplementary Table 2, and bile acid abbreviations are listed in Supplementary Table 3. BA, bile acid; BL, baseline; LOD, limit of detection; M, months; RBL, fecal microbiota, live-jslm; W, weeks.
非 KM Figure
Figure 7Figure 7. A , Secondary-to-primary bile acid ratios in treatment responders and nonresponders. Data are presented as geometric mean ± SEM of the S:P ratios over time. B , Correlation of ratios to the Microbiome Health Index. The red dotted line indicates the index cutoff point for dysbiosis, log(7.2). BA, bile acid; MHI-A, Microbiome Health Index for postantibiotic dysbiosis; RBL, fecal microbiota, live-jslm; S:P, secondary-to-primary bile acid ratio.
非 KM Figure